Spravato is Coming Soon!

As part of Syzygy’s commitment to providing innovative, evidence-informed options for individuals experiencing treatment-resistant depression, Dr. Jenia Malysh will soon be adding Spravato as a treatment for those who qualify for this cutting edge therapy.

Spravato is a form of Ketamine therapy that is currently FDA-approved for treatment-resistant depression, and ongoing research continues to explore its potential benefits for other mental health conditions. While ketamine itself can be a powerful tool, the preparation and integration process — the work we do before and after treatment — is just as important in supporting meaningful, lasting shifts. 

When this service becomes available, our approach will emphasize careful screening to determine if ketamine is an appropriate fit for your needs and health history, intentional preparation to help you approach the experience with clarity and safety, and post-treatment psychedelic integration support, helping you process any insights or emotions that emerge and weave them into your life so you can move forward.